1. Home
  2. BEAM vs CLOV Comparison

BEAM vs CLOV Comparison

Compare BEAM & CLOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

N/A

Current Price

$23.08

Market Cap

2.8B

Sector

Health Care

ML Signal

N/A

Logo Clover Health Investments Corp.

CLOV

Clover Health Investments Corp.

N/A

Current Price

$4.94

Market Cap

2.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BEAM
CLOV
Founded
2017
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.8B
2.6B
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
BEAM
CLOV
Price
$23.08
$4.94
Analyst Decision
Strong Buy
Buy
Analyst Count
15
5
Target Price
★ $49.85
$5.60
AVG Volume (30 Days)
1.8M
★ 4.3M
Earning Date
11-03-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 82.31
38.03
EPS
N/A
★ 0.11
Revenue
$24,000.00
★ $1,924,308,000.00
Revenue This Year
N/A
$55.33
Revenue Next Year
N/A
$22.64
P/E Ratio
★ N/A
$44.45
Revenue Growth
33.33
★ 40.34
52 Week Low
$20.23
$1.58
52 Week High
$38.26
$5.59

Technical Indicators

Market Signals
Indicator
BEAM
CLOV
Relative Strength Index (RSI) 40.33 57.11
Support Level $22.65 $4.17
Resistance Level $28.19 $5.09
Average True Range (ATR) 1.92 0.29
MACD -0.33 0.04
Stochastic Oscillator 0.07 64.52

Price Performance

Historical Comparison
BEAM
CLOV

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.

About CLOV Clover Health Investments Corp.

Clover Health Investments Corp is a healthcare technology company. It focuses on empowering Medicare physicians to proactively manage chronic diseases through its proprietary software platform, Clover Assistant. This cloud-based solution provides personalized insights to physicians, enabling early detection and management of chronic conditions. It operates in one segment: Insurance, through which it offers PPO and HMO plans to Medicare Advantage members in several states.

Share on Social Networks: